Follicular Lymphoma | Tumor

FDA Approves Yescarta for Third-Line Treatment of Relapsed or Refractory Follicular Lymphoma

March 6th 2021, 2:06am


This accelerated FDA approval is the first CAR T-cell therapy approved for the treatment of patients with indolent follicular lymphoma.

Bringing Clinical Trials in Cancer Closer to Home

February 17th 2021, 8:00pm


Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.

FDA Approves Ukoniq in Certain Previously Treated Patients with Marginal Zone and Follicular Lymphoma

February 5th 2021, 8:57pm


The Food and Drug Administration has granted an accelerated approval to Ukoniq for the treatment of certain adults with previously treated relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

The Top 5 News and Updates in Follicular Lymphoma That Patients May Have Missed in 2020

December 30th 2020, 10:00pm


A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

One-Half Teaspoon

December 26th 2020, 7:00pm


Aileen Holthaus writes about her first day of chemotherapy for follicular lymphoma, and the challenges it presented.

Novel Drugs Look Promising in the Treatment of Follicular Lymphoma

November 4th 2020, 4:00pm


One recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma, according to Dr. Germame Ajebo.

Trading Places: A Father and Daughter's Journey with Lymphoma

October 30th 2020, 6:00pm


Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.

Tazverik a Safe and Effective Option for Heavily Pretreated Patients with Follicular Lymphoma

October 27th 2020, 9:00pm


In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.

Aliqopa in Combination with Rituxan Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma

October 16th 2020, 6:00pm


A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.

Follicular Lymphoma Treatment Could Rely on Immunotherapy in Therapy Sequencing

October 15th 2020, 9:00pm


Follicular lymphoma treatment options are changing, and according to one expert, immunotherapy could become a major part of therapy sequencing.